Case Report: Concurrent Resistance and Aerobic Training Regulate Adiponectin Expression and Disease Severity in Multiple Sclerosis: A Case Study.
EDSS
HMW oligomers
adiponectin
multiple sclerosis
training
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
05
2020
accepted:
30
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
9
1
2021
Statut:
epublish
Résumé
Adapted exercise is an effective non-pharmacological tool to improve functional, cognitive, and psychological parameters in multiple sclerosis (MS), in association with increased quality of life (QoL) and decreased disease severity. Adipose tissue, through the production of different adipokines, is involved in regulating energy metabolism and inflammation. Adiponectin, increased in MS, circulates as oligomers of low (LMW), medium (MMW), and high molecular weight (HMW), the latter mediating the main biological effects. The aim of study was to evaluate the effects of 4 months training at moderate intensity [65% heart rate reserve (HRR)] on BMI, adiponectin, and QoL in a volunteer with secondary progressive MS. The parameters were evaluated before (T0), after 4 months training (T1), and 6 months after the end of training (T2); total serum adiponectin and its oligomeric profile were evaluated. We found a reduction in BMI (-0.9%) and FAT (-2.6%), an improvement in perceived QoL and a reduced expression of total adiponectin and HMW oligomers together with decreased MS disability level at T1 measured by EDSS. Despite the limitations of a case study, this represent a starting point to understand the influence of exercise in MS and the relationship with adiponectin expression.
Identifiants
pubmed: 33414700
doi: 10.3389/fnins.2020.567302
pmc: PMC7783198
doi:
Types de publication
Case Reports
Langues
eng
Pagination
567302Informations de copyright
Copyright © 2020 Grazioli, Nigro, Cerulli, Borriello, Mancini, Tranchita, Polito, Parisi, Buono and Daniele.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Rehabil Med. 2016 Jul 18;48(7):597-603
pubmed: 27344968
J Clin Med. 2020 Sep 21;9(9):
pubmed: 32967206
Mult Scler Relat Disord. 2019 Apr;29:41-47
pubmed: 30658263
Neuroimmunomodulation. 2013;20(6):341-7
pubmed: 24008588
Mult Scler. 2008 Apr;14(3):383-90
pubmed: 17942508
Clin Interv Aging. 2017 Nov 28;12:2009-2016
pubmed: 29238175
J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):158-62
pubmed: 10406981
J Orthop Sports Phys Ther. 1992;16(5):215-9
pubmed: 18796752
Lab Invest. 2019 Jul;99(7):943-957
pubmed: 30808929
Endocrine. 2017 Aug;57(2):262-271
pubmed: 28616851
Mult Scler. 2017 Oct;23(11):1461-1468
pubmed: 27903934
PLoS One. 2019 Feb 19;14(2):e0197943
pubmed: 30779803
Mult Scler Relat Disord. 2017 Jul;15:11-14
pubmed: 28641765
Mult Scler Relat Disord. 2018 Aug;24:91-100
pubmed: 29982111
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
Clin Chim Acta. 2010 Jun 3;411(11-12):785-93
pubmed: 20188719
Sports Med. 2012 Jan 1;42(1):11-30
pubmed: 22145810
Int J Biochem Cell Biol. 2012 Mar;44(3):563-9
pubmed: 22233975
Eur J Neurol. 2019 Feb;26(2):348-355
pubmed: 30300462
Curr Sports Med Rep. 2019 Dec;18(12):452-457
pubmed: 31834177
Diabetes Metab J. 2015 Oct;39(5):363-72
pubmed: 26566493
J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):34-41
pubmed: 28768821
Asian J Sports Med. 2012 Dec;3(4):267-73
pubmed: 23342225
Curr Opin Neurol. 2020 Jun;33(3):255-261
pubmed: 32304436
Ageing Res Rev. 2019 Mar;50:72-80
pubmed: 30625375
Eur J Immunol. 2013 Aug;43(8):2089-100
pubmed: 23640763
Curr Neurol Neurosci Rep. 2019 Nov 13;19(11):88
pubmed: 31720862
J Neuroimmunol. 2010 Apr 15;221(1-2):7-14
pubmed: 19931190
Psychol Med. 2009 Jan;39(1):3-11
pubmed: 18570697
Mult Scler Relat Disord. 2018 Feb;20:215-219
pubmed: 29433094
Immunotargets Ther. 2016 May 23;5:47-56
pubmed: 27529061
Hormones (Athens). 2012 Jan-Mar;11(1):8-20
pubmed: 22450341
J Mol Cell Biol. 2016 Apr;8(2):120-8
pubmed: 26993045
Ther Adv Neurol Disord. 2013 Jul;6(4):237-48
pubmed: 23858327
J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):733-739
pubmed: 28049634
J Cell Physiol. 2019 Feb 14;:
pubmed: 30767204
Front Immunol. 2017 Jul 31;8:895
pubmed: 28824624
Front Immunol. 2020 Mar 24;11:391
pubmed: 32265906
Int J Mol Sci. 2020 Mar 16;21(6):
pubmed: 32188008
Curr Neuropharmacol. 2010 Sep;8(3):305-15
pubmed: 21358979